Super Sensors is building the data infrastructure layer for a multi-billion dollar market that has never had the right tools.
Non-invasive diagnostics is one of the fastest-growing sectors in healthcare. Breath analysis — measuring volatile organic compounds exhaled with every breath — sits at the center of this revolution. Yet the field has been bottlenecked by the absence of standardized, affordable, home-deployable data collection infrastructure.
Super Sensors is that infrastructure.
← Super Sensors Platform
| Market | Current Size | CAGR | Projected Size |
|---|---|---|---|
| Breath VOC Diagnostics Platforms | $411M | 17.3% | $1.51B by 2033 |
| Breath Analyzers (all types) | $1.2B | 17.4% | $5.12B by 2034 |
| Breath Biopsy Testing | $1.42B | 5.97% | $2.39B by 2034 |
| Electronic Nose Market | $146M | 12.3% | $293M by 2031 |
| Ketone Breath Meter Market | $164M | 7.5% | $236M by 2030 |
Super Sensors targets the $80–$150M and rapidly growing research-tool segment within these markets — a segment with no purpose-built, affordable, multi-sensor home data collection platform today.
Lab-bound. GC-MS. Clinical-grade instrumentation. Not designed for home deployment or large study cohorts.
Research-grade. Home-deployable. Multi-sensor. App-connected. The only platform in this space.
Single-analyte. No data export. Not configurable. Not research-grade. Not suitable for studies.
The departure of Biosense from the market in 2024 removed the most clinically credible consumer breath monitor, leaving a gap. Simultaneously, no company offers a researcher-configurable, home-deployable, multi-TGS-sensor data collection kit at accessible pricing. This is Super Sensors' opportunity window.
200–500 active global research groups studying breath biomarkers
Contract research organizations needing standardized breath data collection for clinical endpoints
40–100 companies building breath-based diagnostic or ML applications
Companies building diabetes, metabolic, and wellness platforms seeking non-invasive biomarker data
Labs and producers using VOC sensing for quality, freshness, and fermentation monitoring
Hardware companies using the platform as a development kit before custom device investment
Deployed in real home clinical deployment — not a prototype. Real patients, real homes, real longitudinal data.
Captures BG, diet, session metadata alongside every breath reading. Competitors capture sensor signals only — useless for algorithm development.
Configurable for any VOC target. One hardware platform serves diabetes, ketone, cancer biomarker, e-nose, and food safety applications.
Opens a previously inaccessible market segment. At $1,200–$4,000, the platform is within reach of academic labs, early-stage startups, and standard grant budgets.